Clinical trials

CTMX-904-101, a Phase 1/1b open-label study, is now enrolling patients with metastatic or locally advanced unresectable solid tumors.

CX-904 is a conditionally activated T-cell-engaging bispecific designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. CX-904 uses CytomX’s Probody peptide-masking technology to reduce binding to EGFR and CD3 in normal tissues and direct binding towards tumor tissue.

Purpose: The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.

If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.

Start date: February 22, 2022
Estimated Enrollment: 100 Participants
Study Title: A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

BMS-986288, a Phase 1/2 study in patients with advanced solid tumors

BMS-986288 is a next-generation anti-CTLA-4 non-fucosylated Probody therapeutic, designed to be conditionally activated in the tumor microenvironment with enhanced CD16 binding and increased APC-mediated T-cell priming capabilities

Bristol Myers Squibb is enrolling patients in a Phase 1/2 clinical trial (NCT03994601) evaluating BMS-986288 alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers.

Purpose: The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.

Start date: June 21, 2019
Estimated Enrollment: 494 Participants
Study Title: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers